Go Pro
NASDAQ:NEUP

Neuphoria Therapeutics Q3 2025 Earnings Report

Neuphoria Therapeutics logo
$3.95 +0.04 (+1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$3.93 -0.02 (-0.51%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuphoria Therapeutics EPS Results

Actual EPS
$6.55
Consensus EPS
-$0.47
Beat/Miss
Beat by +$7.02
One Year Ago EPS
N/A

Neuphoria Therapeutics Revenue Results

Actual Revenue
$15.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neuphoria Therapeutics Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Tuesday, May 20, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Neuphoria Therapeutics' Q4 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedules

Neuphoria Therapeutics Earnings Headlines

Neuphoria Therapeutics Inc Ordinary Shares NEUP
Neuphoria Therapeutics Inc (NEUP)
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.tc pixel
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

View Neuphoria Therapeutics Profile